143 related articles for article (PubMed ID: 17696994)
1. Brain gene expression correlates with changes in behavior in the R6/1 mouse model of Huntington's disease.
Hodges A; Hughes G; Brooks S; Elliston L; Holmans P; Dunnett SB; Jones L
Genes Brain Behav; 2008 Apr; 7(3):288-99. PubMed ID: 17696994
[TBL] [Abstract][Full Text] [Related]
2. Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6/2 Huntington's disease mice.
Kedaigle AJ; Reidling JC; Lim RG; Adam M; Wu J; Wassie B; Stocksdale JT; Casale MS; Fraenkel E; Thompson LM
Hum Mol Genet; 2020 Jan; 29(2):202-215. PubMed ID: 31696228
[TBL] [Abstract][Full Text] [Related]
3. Early exploratory behavior abnormalities in R6/1 Huntington's disease transgenic mice.
Bolivar VJ; Manley K; Messer A
Brain Res; 2004 Apr; 1005(1-2):29-35. PubMed ID: 15044061
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal analysis of the behavioural phenotype in R6/1 (C57BL/6J) Huntington's disease transgenic mice.
Brooks SP; Janghra N; Workman VL; Bayram-Weston Z; Jones L; Dunnett SB
Brain Res Bull; 2012 Jun; 88(2-3):94-103. PubMed ID: 21272613
[TBL] [Abstract][Full Text] [Related]
5. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation.
Carter RJ; Lione LA; Humby T; Mangiarini L; Mahal A; Bates GP; Dunnett SB; Morton AJ
J Neurosci; 1999 Apr; 19(8):3248-57. PubMed ID: 10191337
[TBL] [Abstract][Full Text] [Related]
6. Wheel running from a juvenile age delays onset of specific motor deficits but does not alter protein aggregate density in a mouse model of Huntington's disease.
van Dellen A; Cordery PM; Spires TL; Blakemore C; Hannan AJ
BMC Neurosci; 2008 Apr; 9():34. PubMed ID: 18380890
[TBL] [Abstract][Full Text] [Related]
7. A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.
Cummings DM; Alaghband Y; Hickey MA; Joshi PR; Hong SC; Zhu C; Ando TK; André VM; Cepeda C; Watson JB; Levine MS
J Neurophysiol; 2012 Jan; 107(2):677-91. PubMed ID: 22072510
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal analysis of the electroencephalogram and sleep phenotype in the R6/2 mouse model of Huntington's disease.
Fisher SP; Black SW; Schwartz MD; Wilk AJ; Chen TM; Lincoln WU; Liu HW; Kilduff TS; Morairty SR
Brain; 2013 Jul; 136(Pt 7):2159-72. PubMed ID: 23801738
[TBL] [Abstract][Full Text] [Related]
9. Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/1 mouse model of Huntington's disease.
Rattray I; Smith EJ; Crum WR; Walker TA; Gale R; Bates GP; Modo M
PLoS One; 2013; 8(12):e84726. PubMed ID: 24367693
[TBL] [Abstract][Full Text] [Related]
10. The novel substituted pyrimidine, KP544, reduces motor deficits in the R6/2 transgenic mouse model of Huntington's disease.
Dey ND; Boersen AJ; Myers RA; York LR; Bombard MC; Lu M; Sandstrom MI; Hulce VD; Lescaudron L; Dunbar GL
Restor Neurol Neurosci; 2007; 25(5-6):485-92. PubMed ID: 18334766
[TBL] [Abstract][Full Text] [Related]
11. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.
Fatoba O; Kloster E; Reick C; Saft C; Gold R; Epplen JT; Arning L; Ellrichmann G
Exp Neurol; 2018 Apr; 302():112-128. PubMed ID: 29309751
[TBL] [Abstract][Full Text] [Related]
12. Sex differences in behavior and striatal ascorbate release in the 140 CAG knock-in mouse model of Huntington's disease.
Dorner JL; Miller BR; Barton SJ; Brock TJ; Rebec GV
Behav Brain Res; 2007 Mar; 178(1):90-7. PubMed ID: 17239451
[TBL] [Abstract][Full Text] [Related]
13. Characterisation of progressive motor deficits in whisker movements in R6/2, Q175 and Hdh knock-in mouse models of Huntington's disease.
Garland H; Wood NI; Skillings EA; Detloff PJ; Morton AJ; Grant RA
J Neurosci Methods; 2018 Apr; 300():103-111. PubMed ID: 28472678
[TBL] [Abstract][Full Text] [Related]
14. Corticosterone dysregulation exacerbates disease progression in the R6/2 transgenic mouse model of Huntington's disease.
Dufour BD; McBride JL
Exp Neurol; 2016 Sep; 283(Pt A):308-17. PubMed ID: 27381424
[TBL] [Abstract][Full Text] [Related]
15. An independent study of the preclinical efficacy of C2-8 in the R6/2 transgenic mouse model of Huntington's disease.
Wang N; Lu XH; Sandoval SV; Yang XW
J Huntingtons Dis; 2013; 2(4):443-51. PubMed ID: 25062731
[TBL] [Abstract][Full Text] [Related]
16. Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse.
Naver B; Stub C; Møller M; Fenger K; Hansen AK; Hasholt L; Sørensen SA
Neuroscience; 2003; 122(4):1049-57. PubMed ID: 14643771
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis.
Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J
Elife; 2021 Apr; 10():. PubMed ID: 33871358
[TBL] [Abstract][Full Text] [Related]
18. An open system for automatic home-cage behavioral analysis and its application to male and female mouse models of Huntington's disease.
Zarringhalam K; Ka M; Kook YH; Terranova JI; Suh Y; King OD; Um M
Behav Brain Res; 2012 Apr; 229(1):216-25. PubMed ID: 22266926
[TBL] [Abstract][Full Text] [Related]
19. Striatal pre-enkephalin overexpression improves Huntington's disease symptoms in the R6/2 mouse model of Huntington's disease.
Bissonnette S; Vaillancourt M; Hébert SS; Drolet G; Samadi P
PLoS One; 2013; 8(9):e75099. PubMed ID: 24040390
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington's disease: behavioral testing and impact of diabetes mellitus.
Lüesse HG; Schiefer J; Spruenken A; Puls C; Block F; Kosinski CM
Behav Brain Res; 2001 Nov; 126(1-2):185-95. PubMed ID: 11704263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
